• Dapps:16.23K
  • Blockchains:78
  • Active users:66.47M
  • 30d volume:$303.26B
  • 30d transactions:$879.24M

Michael Saylor: Bitcoin as an Alternative to Toxic Bonds

user avatar

by Giorgi Kostiuk

10 months ago


At the ICR Conference in Orlando, MicroStrategy founder Michael Saylor made significant statements about Bitcoin and advised companies to rethink their investment strategies.

Key Statements by Michael Saylor

At the ICR Conference in Orlando, Michael Saylor urged companies to buy Bitcoin, describing bonds as 'toxic.' He believes that Bitcoin is suitable for corporate investments.

Comparison of Bitcoin and Bonds Since 2020

Saylor compared the performance of Bitcoin and bonds since 2020. He stated that after MicroStrategy adopted the Bitcoin buying strategy, its value increased, while the value of bonds decreased.

Investment Recommendations for Businesses

Saylor outlined options for companies: continue traditional approaches such as buying U.S. Treasury bonds and conducting buybacks and dividends, or innovate by adding Bitcoin to their investment portfolios. He also criticized companies like Microsoft and Nvidia for not adopting the Bitcoin buying strategy.

Michael Saylor continues to promote Bitcoin as a more attractive investment compared to traditional financial instruments like bonds.

0

Rewards

chest
chest
chest
chest

More rewards

Discover enhanced rewards on our social media.

chest

Other news

Crypto Derivatives Industry Faces Structural Critique

chest

A fresh bout of soulsearching has gripped the crypto derivatives industry as leading market participants argue that the market's structure is fundamentally flawed.

user avatarDavid Robinson

Bitcoin Hyper Revolutionizes Smart Contracts on Bitcoin

chest

Bitcoin Hyper aims to address Bitcoin's limitations by introducing a high-speed execution layer for smart contracts.

user avatarAndrew Smith

BioAge Labs Focuses on Metabolic Aging with AI

chest

BioAge Labs is utilizing machine learning to explore metabolic aging and develop treatments for metabolic disorders.

user avatarAyman Ben Youssef

Neumora Therapeutics Targets Brain Diseases with AI

chest

Neumora Therapeutics is developing AI-driven solutions for treating brain diseases, including schizophrenia and Alzheimer's.

user avatarSon Min-ho

Relay Therapeutics Innovates Drug Discovery with AI

chest

Relay Therapeutics is using its AI-powered platform to enhance drug discovery processes in oncology.

user avatarJacob Williams

AI Advances in Biotech: Nobel Prize Winners and Promising Companies

chest

In 2024, the Nobel Prize in Chemistry was awarded to David Baker, Demis Hassabis, and John Jumper for their groundbreaking work in using machine learning to design entirely new proteins, highlighting the growing role of AI in biotech.

user avatarTando Nkube

Important disclaimer: The information presented on the Dapp.Expert portal is intended solely for informational purposes and does not constitute an investment recommendation or a guide to action in the field of cryptocurrencies. The Dapp.Expert team is not responsible for any potential losses or missed profits associated with the use of materials published on the site. Before making investment decisions in cryptocurrencies, we recommend consulting a qualified financial advisor.